Oruka Therapeutics, Inc. ORKA · Stock Open Oruka Therapeutics, Inc. in new tab
Oruka Therapeutics, Inc. Analysis (ORKA)
Is Oruka Therapeutics, Inc. a good investment? Oruka Therapeutics, Inc. (ORKA) is currently trading at 83.42 USD. Market analysts have a consensus price target of 155.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Oruka Therapeutics, Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -2.86.
Investor FAQ
Does Oruka Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Oruka Therapeutics, Inc.?
Oruka Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -2.04.
Company Profile
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
| Year | Total Dividends |
|---|---|
| ▸2024 |
20.97 USD
|
| Aug. 29, 2024 | 1.6130 |
| Aug. 29, 2024 | 19.3560 |
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 23, 2004 | 1:3 |
| Jan. 28, 2009 | 1:20 |
| March 5, 2013 | 1:6 |
| Sept. 4, 2015 | 1:7 |
| April 4, 2019 | 1:18 |
| Sept. 3, 2024 | 1:12 |
Community Discussion